deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT06840158

Double-blind Comparative Randomized Multicenter

A Double-blind Comparative Randomized Trial to Evaluate the Safety and Efficacy of the Drug Miotox® in Children with Cerebral Palsy

Sponsor: Innopharm LLC

Conditions Cerebral Palsy (CP)
Interventions BOTOX® Miotox (Botulinum toxin type A is a hemagglutinin complex)
Updated 2 times since 2025 Last updated: Feb 17, 2025 Started: Oct 15, 2021 Primary completion: May 15, 2022 Completion: Jun 29, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06840158, this PHASE3 trial focuses on Cerebral Palsy (CP) and remains completed. Sponsored by Innopharm LLC, it has been updated 2 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Mar 2025 – ~Sep 2025 · 6 months · monthly snapshotCompleted~Sep 2025 – present · 10 months · monthly snapshotCompleted

Change History

2 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Mar 2025 — Sep 2025 [monthly]

    Completed PHASE3

    First recorded

Oct 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Innopharm LLC
Data source: Innopharm LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations